Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
must sum to 1). The alternative notation also makes it easier to understand the sub-models of the GTR model, which simply correspond to cases where exchangeability and/or equilibrium base frequency parameters are constrained to take on equal values. A number of specific sub-models have been named, largely based on their original publications:
Protein methods are the techniques used to study proteins. There are experimental methods for studying proteins (e.g., for detecting proteins, for isolating and purifying proteins, and for characterizing the structure and function of proteins, often requiring that the protein first be purified). Computational methods typically use computer programs to analyze proteins. However, many experimental methods (e.g., mass spectrometry) require computational analysis of the raw data.
=== Strategic Alliances === Grifols has pursued public-private alliances around the world. In 2020, Grifols signed an agreement with Egypt’s National Service Projects Organization to establish Grifols Egypt for Plasma Derivatives, a joint venture building the first integrated platform for sourcing and producing plasma medicines in Africa and the Middle East. This was followed by a long-term agreement with Canadian Blood Services in 2022, to help accelerate immunoglobulin self-sufficiency in Canada. Grifols also sought to strengthen and enhance China’s healthcare system by entering into a strategic alliance with Haier Group in late 2023 to further develop the Chinese plasma market, building on a strategic alliance it had established with Shanghai RAAS, a leading Chinese company in the plasma-derivatives sector, in 2020. Between January and March 2024, short seller fund Gotham City Research published several reports questioning Grifols financial accounting. In January 2024, following the first of such reports, Grifols filed a lawsuit against the short seller for making “false and misleading statements”. In February 2024, Grifols rejected what it considered were Gotham's "malicious, false and misleading insinuations" that had the "sole objective of destabilising Grifols and causing doubts amongst institutional investors". In April 2024, Grifols announced it was bringing in independent directors to improve its governance.
A way to provide an investigational therapy to a patient who is not eligible to receive that therapy in a clinical trial, but who has a serious or life-threatening illness for which other treatments are not available. Expanded access allows a patient to receive promising but not yet fully studied or approved therapies when no other treatment option exists. Also called compassionate use trial. (NCI) Experimental
Soybean plants are vulnerable to a wide range of bacterial diseases, fungal diseases, viral diseases, and parasites. The primary bacterial diseases include bacterial blight, bacterial pustule and downy mildew affecting the soybean plant. The Japanese beetle (Popillia japonica) poses a significant threat to agricultural crops, including soybeans, due to its voracious feeding habits. Found commonly in both urban and suburban areas, these beetles are frequently observed in agricultural landscapes where they can cause considerable damage to crops like corn, soybeans, and various fruits. Soybean cyst nematode (SCN) is the worst pest of soybean in the US. Losses of 30% or 40% are common even without symptoms. The corn earworm moth and bollworm (Helicoverpa zea) is a common and destructive pest of soybean growth in Virginia. Soybeans are consumed by whitetail deer which may damage soybean plants through feeding, trampling and bedding, reducing crop yields by as much as 15%. Groundhogs are also a common pest in soybean fields, living in burrows underground and feeding nearby. One den of groundhogs can consume a tenth to a quarter of an acre of soybeans. Chemical repellents or firearms are effective for controlling pests in soybean fields.
Sources: en.wikipedia.org
Next, the plutonium and uranium are available for making nuclear-energy materials, such as new reactor fuel (MOX-fuel) and (plutonium-based) nuclear weapons. Historically some fission products such as Strontium-90 or Caesium-137 were likewise separated for use as radionuclides employed in industry or medicine. The ion-exchange process is also used to separate other sets of very similar chemical elements, such as zirconium and hafnium, which is also very important for the nuclear industry. Physically, zirconium is practically transparent to free neutrons, used in building nuclear reactors, but hafnium is a very strong absorber of neutrons, used in reactor control rods. Thus, ion-exchange is used in nuclear reprocessing and the treatment of radioactive waste. Ion-exchange resins in the form of thin membranes are also used in chloralkali process, fuel cells, and vanadium redox batteries.
=== Cysteine aminopeptidase === Cysteine aminopeptidases, on the other hand, rely on a cysteine amino acid to perform catalysis. These enzymes are part of a broader group of cysteine proteases, all of which carve up proteins by using a nucleophilic cysteine thiol along with one or two other catalytic amino acids in a diad or triad. The triad typically consists of cysteine, histidine, and aspartate amino acids, where the cysteine acts as a nucleophile, the histidine acts as a chemical base, and the aspartate stabilizes the histidine. Examples of cysteine aminopeptidases include cathepsin H and aminopeptidase B.
For example, because of this trend in the sizes of orbitals, a large difference in atomic radii between the first and second members of each main group is seen in groups 1 and 13–17: it exists between neon and argon, and between helium and beryllium, but not between helium and neon. This similarly affects the noble gases' boiling points and solubilities in water, where helium is too close to neon, and the large difference characteristic between the first two elements of a group appears only between neon and argon. Moving helium to group 2 makes this trend consistent in groups 2 and 18 as well, by making helium the first group 2 element and neon the first group 18 element: both exhibit the characteristic properties of a kainosymmetric first element of a group. The group 18 placement of helium nonetheless remains near-universal due to its extreme inertness. Additionally, tables that float both hydrogen and helium outside all groups may rarely be encountered.
Unlike physical disabilities, persons with mental illness are perceived by the public to be in control of their disabilities and responsible for causing them. Furthermore, research respondents are less likely to pity persons with mental illness, instead reacting to psychiatric disability with anger and believing that help is not deserved. The behavioral impact (or discrimination) that results from public stigma may take four forms: withholding help, avoidance, coercive treatment, and segregated institutions.
Sources: en.wikipedia.org
=== Chemical symbol === Deuterium is often represented by the chemical symbol D. Since it is an isotope of hydrogen with mass number 2, it is also represented by 2H. IUPAC allows both D and 2H, though 2H is preferred. A distinct chemical symbol is used for convenience because of the isotope's common use in various scientific processes. Also, its large mass difference with protium (1H) confers non-negligible chemical differences with 1H compounds. Deuterium has a mass of 2.014102 Da, about twice the mean hydrogen atomic weight of 1.007947 Da, or twice protium's mass of 1.007825 Da. The isotope weight ratios within other elements are largely insignificant in this regard.
== History == JWD InfoLogistics started its business with home and office moving services under the name of JVK International Movers Company Limited in 1979. The company later expanded its portfolio of business into the logistics and supply chain industry and converted into a public company and listed in the Stock Exchange of Thailand on September 29, 2015. JWD Group decided to cooperate with Flash Group and Thailand Post to launch the Cold Chain Express named Fuze Post on September 1, 2021. In 2023, JWD InfoLogistics merged with SCG Logistics Management Co.,Ltd (SCGL) and was renamed SCGJWD Logistics Public Company Limited SCGJWD operates in 9 ASEAN countries plus China and has over 2,400 corporate customers.
=== Dehydrated meals and ingredients === Dehydration can reduce the weight of food by 60 to 90 percent by removing water through evaporation. Some foods dehydrate well, such as onions, peppers, and tomatoes. Dehydration often produces a more compact, albeit slightly heavier, result than freeze-drying. Full meals or individual ingredients may be dehydrated. Dehydration of individual ingredients allows the flexibility to cook different meals based on available ingredients, while precooked and dehydrated meals offer greater convenience. Several cookbooks and online stores specialize in dehydrated foods.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.